Status:
COMPLETED
Pars Plana Vitrectomy Combined With Phacoemulsification Cataract Surgery in Phakic Diabetes Retinopathy Patients
Lead Sponsor:
Zhongshan Ophthalmic Center, Sun Yat-sen University
Conditions:
Diabetic Retinopathy
Diabetic Cataract
Eligibility:
All Genders
45+ years
Phase:
NA
Brief Summary
Pars plana vitrectomy (PPV) is one of the most widely used surgical therapies to proliferative diabetic retinopathy in the world. However, as a predictable consequence of PPV surgery, postoperative c...
Detailed Description
The prevalence of diabetes retinopathy is increasing dramatically recent years. Pars plana vitrectomy (PPV) is one of the most widely used surgical therapies to proliferative diabetic retinopathy in t...
Eligibility Criteria
Inclusion
- Proliferative diabetes retinopathy ;
- Age over 45 years old;
- mild-moderate lens opacities(LOCSⅢ : C3N3P3 or below);
- recognition of at least one alphabet in ETDRS chart.
Exclusion
- Long-standing retinal detachment (more than three months), macular affected
- Low Vision or blind on the other eye;
- Macular degeneration, including age-related macular degeneration and Polypoidal choroidal vasculopathy;
- Ocular trauma;
- Glaucoma;
- Hereditary retinopathy;
- Severe lens opacities before the surgery (LOCSⅢ : C4N4P4 or above).
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 5 2022
Estimated Enrollment :
129 Patients enrolled
Trial Details
Trial ID
NCT04729023
Start Date
February 1 2021
End Date
September 5 2022
Last Update
September 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Ophthalmic center, Sun Yat-sen University
Guangzhou, Guangdong, China, 550000